NCT00967590

Brief Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma. Patients will be randomized to receive either RO5036505 (380mg iv infusion once weekly) or placebo for 8 weeks. Patients will be on a standardized inhaled corticosteroid/long-acting beta-agonist regimen during study treatment. Target sample size is 50-100 individuals.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2009

Geographic Reach
2 countries

16 active sites

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 21, 2009

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 28, 2009

Completed
4 days until next milestone

Study Start

First participant enrolled

September 1, 2009

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

August 24, 2016

Status Verified

August 1, 2016

First QC Date

August 21, 2009

Last Update Submit

August 23, 2016

Conditions

Outcome Measures

Primary Outcomes (2)

  • ACQ questionnaire, spirometry assessments, PEFR

    every week up to day 95

  • Safety and tolerability: AEs, spirometry, concomitant medications, laboratory parameters

    assessed every week, laboratory parameters every 3-4 weeks, up to day 95

Secondary Outcomes (1)

  • Pharmacokinetics: AUC, Cmax, t1/2, V steady-state, clearance

    sampling every week up to day 95

Study Arms (2)

1

EXPERIMENTAL
Drug: RO5036505

2

PLACEBO COMPARATOR
Drug: placebo

Interventions

380mg iv infusion once weekly for 8 weeks

1

iv infusion once weekly for 8 weeks

2

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients, 18-70 years of age
  • moderate to severe asthma for \>/=2 years
  • ACQ score \>/= 1.5
  • ICS and LABA regimen at moderate to high dose
  • non-smokers

You may not qualify if:

  • oral corticosteroid use within 4 weeks prior to screening
  • current escalating immunotherapy
  • acute infection/antibiotic therapy within 4 weeks prior to screening, or chronic infection
  • pulmonary disease other than asthma
  • therapy with any approved monoclonal antibody or biologic agent within 12 months prior to screening
  • previous exposure to investigational monoclonal antibodies or biologics

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (16)

Unknown Facility

Little Rock, Arkansas, 72202, United States

Location

Unknown Facility

San Diego, California, 92103, United States

Location

Unknown Facility

Denver, Colorado, 80206, United States

Location

Unknown Facility

Normal, Illinois, 61761, United States

Location

Unknown Facility

River Forest, Illinois, 60305, United States

Location

Unknown Facility

Boston, Massachusetts, 02115, United States

Location

Unknown Facility

St Louis, Missouri, 63130, United States

Location

Unknown Facility

Omaha, Nebraska, 68131, United States

Location

Unknown Facility

Cincinnati, Ohio, 45242, United States

Location

Unknown Facility

Cleveland, Ohio, 44195, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15213, United States

Location

Unknown Facility

Spartanburg, South Carolina, 29303, United States

Location

Unknown Facility

Galveston, Texas, 77555-0561, United States

Location

Unknown Facility

Madison, Wisconsin, 53792, United States

Location

Unknown Facility

Hereford, HR1 2ER, United Kingdom

Location

Unknown Facility

Manchester, M23 9QZ, United Kingdom

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

August 21, 2009

First Posted

August 28, 2009

Study Start

September 1, 2009

Study Completion

August 1, 2010

Last Updated

August 24, 2016

Record last verified: 2016-08

Locations